

Rosa De Vincenzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1152789/publications.pdf>

Version: 2024-02-01

54
papers

2,124
citations

236612

25
h-index

233125

45
g-index

55
all docs

55
docs citations

55
times ranked

2520
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia. <i>Vaccines</i> , 2022, 10, 579.	2.1	27
2	Neoadjuvant chemotherapy followed by conization in stage IB2-III A1 cervical cancer larger than 2 cm: a Pilot study. <i>Fertility and Sterility</i> , 2021, 115, 148-156.	0.5	17
3	High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes. <i>Gynecologic Oncology</i> , 2021, 161, 173-178.	0.6	34
4	HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study. <i>Vaccines</i> , 2021, 9, 643.	2.1	4
5	HPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis. <i>Vaccines</i> , 2021, 9, 816.	2.1	4
6	Are We Facing a New Colposcopic Practice in the HPV Vaccination Era? Opportunities, Challenges, and New Perspectives. <i>Vaccines</i> , 2021, 9, 1081.	2.1	8
7	Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. <i>Vaccines</i> , 2020, 8, 717.	2.1	28
8	Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. <i>Gynecologic Oncology</i> , 2020, 159, 636-641.	0.6	54
9	HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). <i>Vaccines</i> , 2020, 8, 354.	2.1	21
10	MRI in pregnant patients with suspected abdominal and pelvic cancer: a practical guide for radiologists. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 183-192.	0.7	16
11	Effect of age and cone dimensions on cervical regeneration: an Italian multicentric prospective observational study. <i>BMJ Open</i> , 2018, 8, e020675.	0.8	12
12	Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1141-1148.	1.2	3
13	Locally Advanced Cervical Cancer in Pregnancy: Overcoming the Challenge. A Case Series and Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1490-1496.	1.2	16
14	Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group. <i>Clinical Therapeutics</i> , 2015, 37, 156-167.e4.	1.1	26
15	Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1273.	1.0	9
16	Long-term efficacy and safety of human papillomavirus vaccination. <i>International Journal of Women's Health</i> , 2014, 6, 999.	1.1	80
17	Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study. <i>Gynecologic Oncology</i> , 2014, 133, 518-525.	0.6	56
18	HPV vaccine cross-protection: Highlights on additional clinical benefit. <i>Gynecologic Oncology</i> , 2013, 130, 642-651.	0.6	61

#	ARTICLE	IF	CITATIONS
19	Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: Long-term results. <i>Gynecologic Oncology</i> , 2013, 128, 518-523.	0.6	14
20	Bowel Endometriosis with Hemoperitoneum Complicating Pregnancy. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2013, 5, 166-169.	0.3	4
21	Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. <i>British Journal of Cancer</i> , 2012, 107, 37-42.	2.9	40
22	NGR-hTNF and doxorubicin in relapsed ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5059-5059.	0.8	0
23	Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus-Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. <i>Clinical Therapeutics</i> , 2011, 33, 1084-1095.e4.	1.1	13
24	Clinical Performance of Human Papillomavirus E6 and E7 mRNA Testing for High-Grade Lesions of the Cervix. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3895-3901.	1.8	63
25	Treatment of cervical cancer in Italy: Strategies and their impact on the women. <i>Vaccine</i> , 2009, 27, A39-A45.	1.7	13
26	Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. <i>Annals of Oncology</i> , 2007, 18, 1348-1353.	0.6	22
27	An acephalus acardius amorphous fetus in a monozygotic pregnancy with sex discrepancy. <i>Twin Research and Human Genetics</i> , 2006, 9, 697-702.	0.3	6
28	Management of an advanced ovarian cancer at 15 weeks of gestation: Case report and literature review. <i>Gynecologic Oncology</i> , 2005, 97, 693-696.	0.6	64
29	The role of sonographic examination in the follow-up of gynecological neoplasms. <i>Gynecologic Oncology</i> , 2005, 99, 696-703.	0.6	25
30	Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings?. <i>Cancer</i> , 2002, 95, 2500-2507.	2.0	25
31	In vitro evaluation of newly developed chalcone analogues in human cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 305-312.	1.1	84
32	N-Deacetyl-N-aminoacylthiocolchicine Derivatives: Synthesis and Biological Evaluation on MDR-Positive and MDR-Negative Human Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5272-5276.	2.9	18
33	Anti-proliferative activity of a new class of taxanes (14 ^β -hydroxy-10-deacetylbaicatin III derivatives) on multidrug-resistance-positive human cancer cells. , 1997, 72, 844-850.		51
34	Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. <i>European Journal of Cancer</i> , 1996, 32, 877-882.	1.3	95
35	Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. <i>Cancer Letters</i> , 1996, 108, 7-14.	3.2	22
36	Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. , 1996, 68, 340-348.		26

#	ARTICLE	IF	CITATIONS
37	Methyl-p-Hydroxyphenyllactate-esterase activity and type-II estrogen-binding sites in ovarian cancer: Correlation with biological and clinico-pathological parameters. <i>International Journal of Cancer</i> , 1995, 62, 536-541.	2.3	4
38	Bisdioxopiperazine, (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF 187), Enhances the Antiproliferative Effect of Cisplatin on Human Ovarian Cancer Cells. <i>Gynecologic Oncology</i> , 1995, 57, 16-22.	0.6	3
39	Reply to the letter to the editors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 449-450.	1.1	0
40	Quercetin enhances transforming growth factor β 21, secretion by human ovarian cancer cells. <i>International Journal of Cancer</i> , 1994, 57, 211-215.	2.3	42
41	Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 459-464.	1.1	242
42	Clinical significance of cathepsin D in primary ovarian cancer. <i>European Journal of Cancer</i> , 1994, 30, 935-940.	1.3	28
43	Significance of epidermal growth factor receptor expression in primary human endometrial cancer. <i>International Journal of Cancer</i> , 1994, 56, 26-30.	2.3	48
44	Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines. <i>International Journal of Cancer</i> , 1993, 54, 462-466.	2.3	53
45	Type II Estrogen-Binding Sites in Human Ovarian Cancer: Correlation with Estrogen, Progesterone, and Epidermal Growth Factor Receptor. <i>Gynecologic Oncology</i> , 1993, 49, 67-72.	0.6	9
46	Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. <i>European Journal of Cancer</i> , 1992, 28, 1885-1889.	1.3	24
47	Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1992, 83, 183-193.	1.6	19
48	Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). <i>Gynecologic Oncology</i> , 1992, 45, 13-19.	0.6	60
49	Significance of epidermal growth factor receptor in advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1992, 10, 529-535.	0.8	89
50	The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. <i>Leukemia Research</i> , 1992, 16, 497-503.	0.4	49
51	EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance. <i>International Journal of Cancer</i> , 1992, 52, 862-866.	2.3	83
52	Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 255-258.	1.1	120
53	Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. <i>Anti-Cancer Drugs</i> , 1990, 1, 45-48.	0.7	65
54	Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. <i>British Journal of Cancer</i> , 1990, 62, 942-946.	2.9	125